Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma
Open Access
- 14 July 2016
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 22 (14), 3593-3605
- https://doi.org/10.1158/1078-0432.ccr-15-2296
Abstract
Purpose: MYC is a critical driver oncogene in many cancers, and its deregulation in the forms of translocation and overexpression has been implicated in lymphomagenesis and progression of diffuse large B-cell lymphoma (DLBCL). The MYC mutational profile and its roles in DLBCL are unknown. This study aims to determine the spectrum of MYC mutations in a large group of patients with DLBCL, and to evaluate the clinical significance of MYC mutations in patients with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) immunochemotherapy. Experimental Design: We identified MYC mutations in 750 patients with DLBCL using Sanger sequencing and evaluated the prognostic significance in 602 R-CHOP–treated patients. Results: The frequency of MYC mutations was 33.3% at the DNA level (mutations in either the coding sequence or the untranslated regions) and 16.1% at the protein level (nonsynonymous mutations). Most of the nonsynonymous mutations correlated with better survival outcomes; in contrast, T58 and F138 mutations (which were associated with MYC rearrangements), as well as several mutations occurred at the 3′ untranslated region, correlated with significantly worse survival outcomes. However, these mutations occurred infrequently (only in approximately 2% of DLBCL). A germline SNP encoding the Myc-N11S variant (observed in 6.5% of the study cohort) was associated with significantly better patient survival, and resulted in reduced tumorigenecity in mouse xenografts. Conclusions: Various types of MYC gene mutations are present in DLBCL and show different impact on Myc function and clinical outcomes. Unlike MYC gene translocations and overexpression, most MYC gene mutations may not have a role in driving lymphomagenesis. Clin Cancer Res; 22(14); 3593–605. ©2016 AACR.Keywords
Other Versions
Funding Information
- NCI NIH (R01CA138688 and R01CA187415)
- Roche Molecular System, Gilead Sciences Pharmaceutical, Seattle Genetics, Dai Sanyo Pharmaceutical, Adaptive Biotechnology, and HTG Molecular Diagnostics (P50CA136411 and P50CA142509)
- Cancer Center Support (CA016672)
This publication has 50 references indexed in Scilit:
- The genetic landscape of mutations in Burkitt lymphomaNature Genetics, 2012
- Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program StudyLeukemia, 2012
- Analysis of the coding genome of diffuse large B-cell lymphomaNature Genetics, 2011
- Overlapping activation-induced cytidine deaminase hotspot motifs in Ig class-switch recombinationProceedings of the National Academy of Sciences of the United States of America, 2011
- Combinatorial effects of microRNAs to suppress the Myc oncogenic pathwayBlood, 2011
- Phosphorylation Regulates c-Myc's Oncogenic Activity in the Mammary GlandCancer Research, 2011
- Origin of Chromosomal Translocations in Lymphoid CancerCell, 2010
- AID Produces DNA Double-Strand Breaks in Non-Ig Genes and Mature B Cell Lymphomas with Reciprocal Chromosome TranslocationsMolecular Cell, 2009
- Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell–like diffuse large B cell lymphomaThe Journal of Experimental Medicine, 2007
- Evasion of the p53 tumour surveillance network by tumour-derived MYC mutantsNature, 2005